Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, “Sun Pharma”)) and Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) (“Checkpoint”) announce that they have entered into an agreement by which Sun Pharma will acquire Checkpoint, an immunotherapy and targeted oncology company. Checkpoint is a Nasdaq-listed commercial-stage company focused on developing novel treatments for patients with solid tumor cancers. The upfront cash payment of $4.10 per share of common stock represents a premium of approximately 66.0% to Checkpoint’s closing share price on March 7, 2025, the last trading day prior to today’s announcement.
Read the full article: Sun Pharma to Acquire Checkpoint Therapeutics //
Source: https://www.prnewswire.com/news-releases/sun-pharma-to-acquire-checkpoint-therapeutics-302396492.html